Trial Profile
A Phase 1b, Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TT301/MW189 Administered Intravenously to Healthy Volunteers
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs TT 301 (Primary)
- Indications Alzheimer's disease; CNS disorders; Rheumatoid arthritis
- Focus Adverse reactions
- 22 Jan 2018 New trial record